When a TNF inhibitor stops working for ankylosing spondylitis, the situation is not hopeless — and it is more common than many patients realize. Roughly one-third of people with axial spondyloarthritis fail their first anti-TNF therapy within the first two years, leaving them searching for a drug that actually controls the pain, stiffness, and progressive spinal fusion that define this disease. The good news is that several newer medications now exist specifically for this population. Bimekizumab, a dual IL-17A and IL-17F inhibitor approved by the FDA in September 2024 under the brand name Bimzelx, represents the newest option and has shown strong results in clinical trials for patients who need something beyond traditional TNF blockers.
IL-17A inhibitors like secukinumab and ixekizumab, along with oral JAK inhibitors such as upadacitinib, round out a growing toolkit that rheumatologists can draw from when the first-line approach falls short. For caregivers and families navigating dementia alongside other chronic conditions, understanding these treatment advances matters more than it might seem at first glance. Chronic pain from undertreated ankylosing spondylitis can worsen cognitive decline, disrupt sleep, limit mobility, and accelerate the functional losses that dementia already imposes. An older adult living with both conditions — or a caregiver managing their own AS while providing round-the-clock support — needs to know that alternatives exist and that giving up on treatment is not the answer. This article walks through the specific drugs available after TNF failure, what the latest clinical evidence says about switching strategies, and practical considerations for discussing these options with a rheumatologist.
Table of Contents
- What New Drug Works for Ankylosing Spondylitis When TNF Inhibitors Fail?
- IL-17 Inhibitors That Preceded Bimekizumab and Still Hold Their Ground
- JAK Inhibitors Offer an Oral Alternative for TNF-Refractory Disease
- Switching Drug Class Versus Cycling Within TNF Inhibitors — What the Evidence Actually Shows
- Why Treatment Timing May Matter Less Than We Thought
- Managing AS Treatment Complexity Alongside Dementia Care
- Where AS Treatment Is Heading
- Conclusion
- Frequently Asked Questions
What New Drug Works for Ankylosing Spondylitis When TNF Inhibitors Fail?
Bimekizumab is the most recently approved medication for ankylosing spondylitis and the first drug designed to simultaneously block both IL-17A and IL-17F, two inflammatory cytokines that drive the joint inflammation and bone damage in AS. Earlier IL-17 drugs only targeted IL-17A, leaving IL-17F to continue fueling the disease process. The fda granted approval in September 2024 based on the Phase 3 BE MOBILE 1 and BE MOBILE 2 trials, which met their primary endpoint of ASAS40 response at Week 16 compared to placebo across all ranked secondary endpoints. In a network meta-analysis, bimekizumab achieved higher ASAS20 response rates at 12 to 16 weeks compared with secukinumab in biologic-naïve AS patients, suggesting that blocking both cytokines may offer a meaningful clinical advantage. The recommended dose is 160 mg given as a subcutaneous injection every four weeks, which is a manageable schedule for most patients.
For someone who has spent months or years on a TNF inhibitor that gradually lost effectiveness — a scenario rheumatologists call secondary failure — bimekizumab offers a genuinely different mechanism of action rather than just another variation on the same theme. Consider a 67-year-old patient whose spouse has Alzheimer’s disease: if that patient’s adalimumab stopped controlling their back pain and stiffness, switching to bimekizumab could restore enough mobility and comfort to continue functioning as a caregiver, rather than becoming a second person in the household who needs daily assistance. However, bimekizumab is not the only option after TNF failure, and it may not be the right choice for everyone. Patients with a history of inflammatory bowel disease, for instance, need careful evaluation before starting any IL-17 inhibitor because these drugs can sometimes worsen gut inflammation. The decision about which drug to try next should always involve a detailed conversation with a rheumatologist who understands the full medical picture.
IL-17 Inhibitors That Preceded Bimekizumab and Still Hold Their Ground
Before bimekizumab arrived, two IL-17A inhibitors had already established themselves as credible alternatives for AS patients who could not tolerate or did not respond to TNF blockers. Secukinumab, marketed as Cosentyx, demonstrated efficacy in both TNF-naïve and TNF-experienced patients with active ankylosing spondylitis in the MEASURE 2 study. Subcutaneous secukinumab significantly improved signs and symptoms compared to placebo in three of four Phase 3 trials, giving rheumatologists their first real alternative to the TNF inhibitor class. Ixekizumab, sold as Taltz, was specifically studied in the TNF-failure population through the COAST-W trial, which enrolled 316 patients who had previously failed or could not tolerate TNF inhibitors. At Week 16, ASAS40 response rates were 30.6 percent for those receiving ixekizumab every two weeks and 25.4 percent for those dosed every four weeks, compared with just 12.5 percent for placebo. These numbers deserve some honest context.
An ASAS40 response means a 40 percent improvement in disease activity — it does not mean the disease is gone. Even in the better-performing ixekizumab group, roughly 70 percent of TNF-failure patients did not achieve that threshold at 16 weeks. this is not a criticism of the drugs so much as a reminder that ankylosing spondylitis after TNF failure is genuinely difficult to treat, and expectations should be realistic. Some patients will experience dramatic improvement, others will see modest gains that nonetheless make a real difference in daily function, and some will need to try yet another approach. A limitation worth noting: if a patient failed a TNF inhibitor due to an infection or other safety concern rather than lack of efficacy, the calculus changes. Someone whose TNF blocker was stopped because of recurrent infections might face similar risks with IL-17 inhibitors, which also suppress parts of the immune system. In these cases, the conversation with a rheumatologist becomes especially important, and the risk-benefit analysis may look quite different than it does for someone whose drug simply stopped working.
JAK Inhibitors Offer an Oral Alternative for TNF-Refractory Disease
For patients who prefer a pill over an injection — or who have not responded adequately to biologic therapies — JAK inhibitors represent a fundamentally different approach. Upadacitinib, brand name Rinvoq, received FDA approval in April 2022 specifically for adults with active ankylosing spondylitis who had an inadequate response or intolerance to one or more TNF blockers. Unlike biologics that target a single extracellular protein, JAK inhibitors work inside the cell by blocking the Janus kinase enzymes that transmit inflammatory signals from multiple cytokine pathways simultaneously. The long-term data for upadacitinib in this population is particularly encouraging. The SELECT-AXIS 2 trial’s two-year follow-up, published in 2024 and 2025, showed that at Week 104, 64.9 percent of biologic-refractory AS patients achieved an ASAS40 response, with a mean ASDAS improvement of negative 2.1 from baseline. That level of sustained response in patients who had already failed biologics is noteworthy.
Tofacitinib, another JAK inhibitor marketed as Xeljanz, is also recommended by the Mayo Clinic for patients who have tried one or more TNF inhibitors without improvement, though it carries its own set of considerations. For example, a 72-year-old retired teacher with AS who dreads injections and also manages mild cognitive impairment might find that a daily oral tablet fits more naturally into a simplified medication routine overseen by a caregiver. However, JAK inhibitors come with safety signals that biologics generally do not. The 2025 British Society for Rheumatology guideline notes that TNF or IL-17 inhibitors are generally preferred over JAK inhibitors as first-line biologics due to more extensive evidence and clinical experience. Regulatory agencies have flagged increased risks of cardiovascular events, malignancy, and thrombosis with certain JAK inhibitors, particularly in older adults — precisely the population most likely to also be dealing with dementia-related care needs. This does not mean JAK inhibitors should be avoided, but it does mean the decision requires a careful weighing of cardiovascular risk factors, age, and the severity of the AS itself.
Switching Drug Class Versus Cycling Within TNF Inhibitors — What the Evidence Actually Shows
One of the most practical questions a patient faces after TNF failure is whether to switch to a completely different drug class or simply try a second TNF inhibitor. The assumption for years was that switching classes would be superior — if the TNF pathway did not work, why keep targeting it? The ROC-SpA trial, a randomized study conducted across 31 French centers with 300 patients who had failed first-line TNF inhibitor therapy, directly tested this assumption and produced a surprising result. Switching to an IL-17 inhibitor was not superior to cycling to a second TNF inhibitor. The ASAS40 response rate at Week 24 was 15.2 percent for the IL-17 switch group compared with 14.5 percent for the TNF cycling group — a difference so small it was not statistically significant. No meaningful differences emerged at 12 or 52 weeks for ASAS40, ASAS20, partial remission, or ASDAS-CRP scores either.
The implication is that both strategies are equally valid, and the choice between them can be based on other factors: patient preference, insurance coverage, comorbidities, or convenience of the dosing schedule. This finding has real-world consequences. If a patient’s insurance covers a second TNF inhibitor but requires a lengthy prior authorization process for an IL-17 drug, there is no compelling clinical reason to fight that battle. Conversely, if someone had a specific side effect from TNF inhibition — say, worsening of pre-existing heart failure, which TNF blockers can exacerbate — switching to an IL-17 inhibitor makes sense on safety grounds even though the efficacy data does not show a clear advantage. The tradeoff is not about one class being better than the other; it is about matching the drug to the individual patient’s complete clinical picture.
Why Treatment Timing May Matter Less Than We Thought
A widely held belief in rheumatology has been that starting biologic therapy early in the course of ankylosing spondylitis produces better long-term outcomes. The logic seems intuitive: catch the inflammation before it causes irreversible structural damage. But a January 2026 Medscape analysis challenged this assumption, finding not much gain from starting TNF inhibitors early in axial spondyloarthritis. If confirmed by further research, this could meaningfully shift how rheumatologists approach treatment decisions. For patients and caregivers, this finding carries a cautionary note.
It does not mean that treatment can be indefinitely delayed or that AS should be ignored until it becomes severe. What it suggests is that the window for starting biologics may be wider than previously thought, and that a few months spent optimizing NSAID therapy, pursuing physical therapy, or sorting out insurance coverage for a biologic may not result in the catastrophic structural progression that patients are sometimes warned about. This is particularly relevant for someone juggling multiple medical appointments — their own rheumatology visits alongside neurology appointments for a spouse with dementia — where the practical logistics of starting a new biologic can be genuinely overwhelming. The limitation here is important: this is a single analysis, and the broader rheumatology community has not yet reached consensus on revising treatment timing recommendations. The 2025 British Society for Rheumatology guideline still recommends TNF inhibitors, IL-17 inhibitors, or JAK inhibitors for axSpA patients with persistently high disease activity, without suggesting that early treatment is unnecessary. Patients should not use this finding as a reason to skip treatment but rather as reassurance that a thoughtful, measured approach to treatment decisions is clinically defensible.
Managing AS Treatment Complexity Alongside Dementia Care
When ankylosing spondylitis coexists with cognitive decline — whether in the same person or within a caregiving relationship — medication management becomes exponentially more complicated. Biologic injections require proper storage, correct technique, and adherence to a schedule that someone with progressing dementia may not be able to manage independently. A JAK inhibitor pill might seem simpler, but it also requires daily adherence that can slip when cognitive function declines.
Practical strategies can help. A caregiver managing a loved one’s AS treatment might set up a biologic injection schedule that aligns with other recurring appointments, use a medication management app with reminders, or ask the rheumatologist’s office about nurse-administered injections during clinic visits. For patients on every-four-week bimekizumab or secukinumab injections, the monthly schedule is actually more manageable than daily oral medications for someone with memory difficulties. The key is matching the treatment regimen not just to the disease but to the cognitive and logistical realities of the household.
Where AS Treatment Is Heading
The landscape for ankylosing spondylitis treatment after TNF failure has changed more in the past three years than in the preceding decade. The approval of bimekizumab as a dual IL-17 inhibitor, the strong long-term data for upadacitinib in biologic-refractory patients, and the ROC-SpA trial’s evidence that switching and cycling are equivalent strategies have collectively given rheumatologists — and their patients — far more flexibility than before.
Looking ahead, the research community is likely to focus on identifying biomarkers that predict which patients will respond to which drug class, potentially ending the trial-and-error approach that currently defines post-TNF treatment. The 2026 findings questioning the urgency of early TNF initiation may also prompt new studies examining whether certain patients can safely start with IL-17 or JAK inhibitors as first-line therapy, bypassing TNF inhibitors altogether. For the millions of people living with AS worldwide, and for the caregivers whose own health depends on keeping chronic conditions controlled, these developments represent a genuine expansion of what is possible.
Conclusion
Failing a TNF inhibitor is not the end of the road for ankylosing spondylitis treatment. Bimekizumab, approved in September 2024 as the first dual IL-17A and IL-17F inhibitor, offers a new mechanism of action with strong clinical trial support. IL-17A inhibitors like secukinumab and ixekizumab have proven track records in TNF-experienced patients, and JAK inhibitors such as upadacitinib provide an oral alternative with impressive two-year durability data. The ROC-SpA trial’s finding that switching drug classes is no better than cycling within the TNF class gives both patients and physicians more freedom to choose based on individual circumstances rather than rigid treatment algorithms.
For anyone managing AS alongside dementia care responsibilities — whether as a patient, a caregiver, or both — the practical takeaway is to bring these options to your next rheumatology appointment. Ask specifically about bimekizumab if you have failed a TNF inhibitor. Discuss whether a JAK inhibitor’s oral convenience outweighs its safety considerations in your particular case. And recognize that the treatment you settle on should account not just for your inflammatory disease but for the full complexity of your life, including the cognitive and logistical demands that dementia places on a household.
Frequently Asked Questions
What is bimekizumab, and how is it different from other IL-17 inhibitors?
Bimekizumab (Bimzelx) is the first drug to block both IL-17A and IL-17F simultaneously. Earlier IL-17 drugs like secukinumab and ixekizumab only target IL-17A. By inhibiting both cytokines, bimekizumab addresses a broader range of the inflammatory signaling that drives ankylosing spondylitis. It was FDA-approved in September 2024 for AS, nr-axSpA, and psoriatic arthritis, and is given as a 160 mg subcutaneous injection every four weeks.
If my TNF inhibitor fails, should I switch to a different drug class or try another TNF inhibitor?
The ROC-SpA trial, conducted across 31 French centers with 300 patients, found that switching to an IL-17 inhibitor was not superior to trying a second TNF inhibitor. ASAS40 response rates at Week 24 were 15.2 percent versus 14.5 percent, with no significant differences at any time point. Both approaches are considered equally valid, so the decision can be based on factors like insurance coverage, side effect profiles, and personal preference.
Are JAK inhibitors safe for older adults with ankylosing spondylitis?
JAK inhibitors like upadacitinib and tofacitinib are effective options, but they carry safety signals that require careful consideration in older patients, including increased risks of cardiovascular events, malignancy, and thrombosis. The 2025 British Society for Rheumatology guideline notes that TNF and IL-17 inhibitors are generally preferred over JAK inhibitors as first-line biologics due to more extensive clinical experience. However, JAK inhibitors remain an important option when biologics are not appropriate or have failed.
How common is it for TNF inhibitors to stop working in ankylosing spondylitis?
About one-third of axial spondyloarthritis patients fail their first anti-TNF therapy within the first two years. This can happen because the body develops antibodies against the drug, because the drug was not the right mechanism for that individual’s disease, or because of side effects that make continuation impossible. It is common enough that rheumatologists consider it a routine part of treatment planning rather than an unusual setback.
Does starting TNF inhibitor treatment early lead to better outcomes?
This has been the conventional assumption, but a January 2026 Medscape analysis found not much gain from starting TNF inhibitors early in axial spondyloarthritis. This does not mean treatment should be delayed indefinitely, but it does suggest the treatment window may be wider than previously believed. Current guidelines still recommend prompt treatment for persistently high disease activity.
Can someone with cognitive decline manage biologic injections for ankylosing spondylitis?
It depends on the stage of cognitive impairment. Monthly subcutaneous injections like bimekizumab or secukinumab may actually be easier to manage than daily oral medications for someone with memory difficulties, especially with caregiver support or nurse-administered options. Discuss the specific cognitive and logistical situation with both the rheumatologist and neurologist to find the most manageable regimen.
